Cytokinetics’ (CYTK) “Buy” Rating Reaffirmed at HC Wainwright
HC Wainwright reissued their buy rating on shares of Cytokinetics (NASDAQ:CYTK – Free Report) in a research note released on Tuesday,Benzinga reports. They currently have a $120.00 price target on the biopharmaceutical company’s stock. CYTK has been the topic of a number of other research reports. Stifel Nicolaus started coverage on shares of Cytokinetics in […]
HC Wainwright reissued their buy rating on shares of Cytokinetics (NASDAQ:CYTK – Free Report) in a research note released on Tuesday,Benzinga reports. They currently have a $120.00 price target on the biopharmaceutical company’s stock. CYTK has been the topic of a number of other research reports. Stifel Nicolaus started coverage on shares of Cytokinetics in […]